Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany

Zorica Vesovic, Kathleen Herkommer, Walther Vogel, Thomas Paiss, Christiane Maier

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Background: A thymidine to cytosine transition (designated A2 variant) in the promoter region of CYP17 has previously been associated with a familial history of prostate cancer in North American families. The purpose of the present study was to determine whether this correlation could be replicated in a European population. Materials and Methods: Case-control comparisons were performed by modelling a dominant (A1/A2 + A2/A2 vs. A1/A1) and a recessive (A2/A2 vs. A1/A2 + A1/A1) effect of the promoter modification. Results: An insignificant overrepresentation of homozygous carriers of the A2 allele (recessive effect) was found in sporadic cases, as compared to controls. However, the A2 variant was not related to familial disease. Conclusion: Our results do not suggest a role of CYP17 as a high-risk susceptibility gene for familial prostate cancer, nor as a modifier for the disease risk in the European population.

Original languageEnglish
Pages (from-to)1303-1307
Number of pages5
JournalAnticancer Research
Issue number2 B
StatePublished - Mar 2005
Externally publishedYes


  • Association
  • CYP17
  • Familial prostate cancer
  • Polymorphism


Dive into the research topics of 'Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany'. Together they form a unique fingerprint.

Cite this